Resources Contact Us Home
Browse by: INVENTOR PATENT HOLDER PATENT NUMBER DATE
 
 
Fujisawa Pharmaceutical Co., Ltd. Patents
Assignee:
Fujisawa Pharmaceutical Co., Ltd.
Address:
Osaka, JP
No. of patents:
840
Patents:


1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17










Patent Number Title Of Patent Date Issued
RE30752 Oxime carbonates September 29, 1981
Novel carbonic acid esters are disclosed which are useful in a process for introducing esterified carboxy-type protective groups on amino and/or imino groups in amino and/or imino group-containing compounds for the temporary protection of said amino and/or imino groups. Additionally,
D323389 Medical fluid container January 21, 1992
D306967 Bottle April 3, 1990
D250542 Container for solid air freshener December 12, 1978
7629366 Aminoalcohol derivatives December 8, 2009
The present invention relates to a compound formula [I]: ##STR00001## wherein ##STR00002## ect., X is bond, --CH.sub.2--, ##STR00003## etc., Y is bond, --O--(CH.sub.2).sub.n-- (in which n is 1, 2, 3 or 4), etc., Z is cyano, tetrazolyl, etc., R.sup.1 is hydrogen, lower alkyl,
7060721 Imidazole compounds and medicinal use thereof June 13, 2006
Imidazole compounds represented by general formula (I): ##STR00001## wherein each symbol is as defined in the specification, and salts thereof, and a pharmaceutical composition containing same are provided. These compounds are useful in treating the diseases curable based on a hypogl
7029860 Amyloid-.beta. protein aggregation-regulating factors April 18, 2006
The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-.beta. protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-.beta. protein; and th
6979461 Method for producing liposome preparation December 27, 2005
An object of the present invention is to provide a method for producing a liposome preparation having excellent rapid action and excellent redispersion into aqueous medium. The present invention provides a method for producing a liposome preparation by vacuum drying wherein liposome
6967197 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors November 22, 2005
A compound of formula (I) in which R.sup.1 is halo, lower alkoxy, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heterecyclic group or optionally substituted lower alkynyl, R.sup.2 is amidated carboxy, R.sup.3 is hydrogen or acyl, Ar is aryl or he
6960435 Amyloid .beta. protein agglutination-controlling factor November 1, 2005
The present invention provides: proteins suppressing or promoting the aggregation or deposition of amyloid-.beta. protein; polynucleotides encoding the proteins; a method for screening a compound suppressing or promoting the aggregation or deposition of amyloid-.beta. protein; and th
6927230 Triazole derivatives August 9, 2005
A compound of the formula (I): ##STR1##wherein R.sup.1 is lower alkyl which is optionally substituted with halogen, cyano, N,N-di(lower)alkylcarbamoyl, phenyl optionally substituted with halogen, or heterocyclic group, cyclo(lower)alkyl, lower alkynyl, or N,N-di(lower)alkylcarb
6924278 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists August 2, 2005
This invention relates to piperazine derivatives of the formula: ##STR1##wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same f
6911469 Sulfonamide compounds and pharmaceutical use thereof June 28, 2005
A sulfonamide compound of the formula (I):wherein R.sup.1 is alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like
6908940 Imidazole compounds and their use as adenosine deaminase inhibitors June 21, 2005
Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I) wherein R.sup.1 is aryloxy, or aryl which is optionally substituted with suitable substituent(s); R.sup.2 is lower alkyl; R.sup.3 is hydroxy or protected hydroxy; and -A- is lower alkylene,
6890934 Sulfonamide compounds and uses thereof as medicines May 10, 2005
The present invention relates to a sulfonamide compound of the formula (I): ##STR1##wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the d
6890909 Brain-protective agent May 10, 2005
A brain-protective agent containing an NF-.kappa.B decoy. In brain diseases, the brain can be particularly effectively protected against brain disorders (for example, cerebral vasospasm following a subrachnoidal hemorrhage and apoptosis of the nerve cells following a cerebrovasucular
6884868 Cyclic hexapeptides having antibiotic activity April 26, 2005
This invention relates to new polypeptide compound represented by general formula (I), wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory
6884774 Cyclic hexapeptide derivatives April 26, 2005
This invention relates to new polypeptide compound represented by the general formula (I) wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are as defined in the description or a salt thereof which has antimicrobial activities (especially, antifungal activities), inhibitory
6884433 Sustained release formulation containing tacrolimus April 26, 2005
Sustained release formulation containing tacrolimus or its hydrate is provided. The time (T63.2%) required for 63.2% of the maximum amount of tacrolimus or its hydrate to be dissolved is 0.7 to 15 hours. The time is measured in accordance to the Japanes Pharmacopocia, the 13-th edition,
6881341 Method for separating lactone-containing high-molecular weight compounds April 19, 2005
A method for separating a lactone-containing high-molecular weight compound comprising subjecting a mixture of a lactone-containing high-molecular weight compound having, as its side-chain, at least one of a lower alkenyl group and a lower alkoxy group and its analogous compound(s) to ei
6878827 Process for producing anhydride of aminothiazole derivative April 12, 2005
This invention provides a novel industrial process for preparation of an anhydride of 2-(2-aminothiazole-4-yl)-2-hydroxy compound.
6875740 Combination of a cyclic hexapeptide with antifungal drugs for treatment of fungal pathogens April 5, 2005
There is described antifungal combination use of known antifungal agents such as the azoles or polyenes in combination with a lipopeptide compound antifungal agent. More particularly, the invention relates to antifungal combination use of azols such as fluconazole voriconazole, itraconaz
6869950 Benzimidazole derivatives March 22, 2005
The present invention provides novel benzimidazole derivatives of the following formula (I) and salts thereof: ##STR1##wherein R.sub.1 represents a lower alkyl group or a lower alkyloxy-lower alkyl group; R.sub.2 represents a hydrogen atom, a halogen atom, an alkyl group having 1 to
6833353 Use of immunosuppressants for MMP mediated diseases December 21, 2004
A new use of immunosuppressant for treating or preventing MMp-medicated diseases is provided. The preferred immunosuppresants are tacrolimus, cyclosporing A or 33-epi-chloro-33-desoxyascomycin (pimecrolimus). Particularly, preferable MMP-mediated diseases are the diseases or conditio
6826033 Aminoalcohol derivatives November 30, 2004
The present invention relates to a compound formula (I) wherein X.sub.1 is bond or --O--CH.sub.2 --, (II) or (III) R.sup.1 is hydrogen or an amino protective group, a is phenyl, indolyl or carbazolyl, each of which may be substituted with one or two substituent(s), and B is hydrogen; hal
6825200 Substituted dipeptides having nos inhibiting activity November 30, 2004
The present invention a compound represented by the formula (I): ##STR1##where the structural variables R.sup.1 -R.sup.6 are defined herein.
6825018 Sorbitol dehydrogenase, gene encoding the same and use thereof November 30, 2004
A gene encoding D-sorbitol dehydrogenase (SLDH); a process for producing SLDH by culturing host cells transformed by an expression vector having the above gene; and a process for processing L-sorbose or 2-keto-L-gulonic acid (2KLGA) by using the above culture. 2KLGA is an important i
6825003 Cyclic lipopeptide acylase November 30, 2004
The present invention provides a cyclic lipopeptide acylase which may effectively deacylate the acyl side chain of a cyclic lipopeptide compound, specifically FR901379 Substance or its analog thereof shown by the following general formula [I], and a process for production of a cyclic
6812235 Beta-alanine derivatives and their use as receptor anatgonists November 2, 2004
A beta-alanine derivative of the formula (I) wherein R.sup.1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R.sup.2 is hydrogen atom or an amino group which may be substituted with an acyl group; R.sup.3 is hydrogen atom or an aryl
6787543 Benzhydryl derivatives September 7, 2004
A compound of the formula (I): in which Z, R.sup.1, R.sup.2, R.sup.8, R.sup.10, R.sup.11, R.sup.12, R.sup.13 and R.sup.14 are each as defined in the description, or a salt thereof. The object compound of the present invention has pharmacological activities such as Tachykinin antagonism,
6774104 Stabilized pharmaceutical composition in lyophilized form August 10, 2004
A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): ##STR1##wherein R.sup.1 is a hydrogen atom or an acyl group and R.sup.2 and R.sup.3 are, the same or different, a hydrogen atom or a hydroxyl grou
6770667 Amide compounds August 3, 2004
The present invention is a compound and pharmaceutical composition comprising a compound of formula (I): ##STR1##wherein R.sup.1 is a 4-(lower) alkyl-imidazol-1-yl or a 4,5-di(lower) alkyl-imidazol-1-yl group, R.sup.2 is a hydrogen atom or a lower alkyl group, and R.sup.3 is a fluore
6765098 Fullerene derivatives July 20, 2004
A novel means for DNA compaction is provided.The object is accomplished by providing a fullerene derivative having 1 to 4 nitrogen-containing hydrophilic side chain(s) or its salt for DNA compaction.DNA compaction can be achieved effectively, and application to gene therapy is also expec
6743776 Cyclohexapeptides having antimicrobial activity June 1, 2004
This invention relates to new polypeptide compounds represented by general formula [I]: ##STR1##wherein R.sup.1 and R.sup.2 are as defined in the description and pharmaceutically acceptable salt thereof which have antimicrobial activities (especially, antifungal activities), inhib
6730776 WF14573 or its salt, production thereof and use thereof May 4, 2004
The present invention provides a new antimicrobial compound WF14573, and a process for producing WF14573 by (a) culturing a WF14573A and/or B-producing microorganism in a nutrient medium and recovering WF14573A and/or B from the resultant cultured broth or (b) deacylating WF14573A an
6727245 Heterobicyclic derivatives April 27, 2004
Heterobicyclic derivatives of the formula: ##STR1##wherein R.sup.1 is aryl which may have suitable substituent(s), ar(lower)alkyl which may have suitable substituent(s), halo(lower)alkyl, protected carboxy(lower)alkyl, acyl(lower)alkyl, heterocyclic group or heterocyclic(lower)alk
6718910 Agents for promoting fattening of animals and method of promoting fattening April 13, 2004
Agents for promoting fattening of animals which contain as the active ingredient(s) at least one member selected from among acids originating in hexoses, non-toxic salts thereof and intramolecular esterification products thereof; and a method of promoting fattening by using these age
6710043 Amide compounds March 23, 2004
This invention relates to amide compounds having the potentiation of the cholinergic activity and represented by formula (I) ##STR1##wherein R.sup.1 is acyl, R.sup.2 is lower alkyl, A is a single bond, --CO-- or --SO.sub.2 --, E is lower alkylene, X is CH or N, Y is a single bond, Q
6709378 Supernatant liquid collector with balance weight forming function and centrifugal apparatus usin March 23, 2004
Primaiy supernatant liquid collector 1 allows blood A to separate into a primary supernatant liquid B and red blood cells by leaving the blood A stationary for a prescribed period of time, and then it discharges the primary supernatant liquid B and physiological saline W in the same amou
6703410 Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carb o March 9, 2004
3-(2,4-Dichlorobenzyl)-2-methyl-N-(pentylsulfonyl)-3H-benzimidazole-5-carbo xamide, a compound having hypoglycemic activity or PDE5 inhibitory effect, has three forms of crystal forms that are distinguishable by their X-ray powder diffraction values. The most crystallographically stable c
6673808 Medicinal compositions January 6, 2004
To provide a pharmaceutical composition comprising a macrolide compound, such as tricyclic compound (I) or its pharmaceutically acceptable salt, a dissolution/absorption promoter, a pharmaceutical base, and optionally a compatibilizing agent and/or a thickener. It is satisfactory in stab
6673807 Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus or cy January 6, 2004
Methods for increasing graft survival time comprising administering the combination of a compound that inhibits the production of nitric oxide and a compound that is a tricyclic macrolide, such as tacrolimus.
6662113 Digital correlation of test samples and the screening of interactions between the same December 9, 2003
A method for determining the physical, chemical, or biological correlation between test samples in group A and test samples in group B. This correlation can be determined by contacting a mixture of test samples selected according to a certain rule from group A with test samples from
6660759 4.5-diaryloxazole compounds with prostaglandin I2 (PGI2) agonistic activity December 9, 2003
Heterocyclic compounds of formula (I), wherein R.sup.1 is carboxy or protected carboxy, R.sup.2 is aryl which may have suitable sustituent(s), R.sup.3 is aryl which may have suitable substituent(s), R.sup.4 is hydrogen, lower alkyl, hydroxy or aryl, A.sup.1 is lower alkylene, (a) is
6656905 Cyclic tetrapeptide compound and use thereof December 2, 2003
A cyclic tetrapeptide compound and use thereof. Especially, a compound WF27082, a process for production of the compound by culturing, in a nutrient medium, a WF27082-producing strain belonging to Acremonium and recovering the compound from a culture broth, a pharmaceutical composition
6630338 Removing deacetylase contaminant from cephalosporin C acylase using cationic surfactant October 7, 2003
An enzyme in a mixture containing the enzyme and a contaminant enzyme is purified by selectively aggregating and precipitating the contaminant enzyme with a surfactant. A deacetylase contaminant is separated from Cephalosporin C acylase using a cationic surfactant in an amount of 0.1 to
6627792 Human T cell-engrafted mouse, method for developing same and use thereof September 30, 2003
The present invention provides a method for developing a human T cell-engrafted mouse, which includes transplanting a human-derived bone tissue into an inbred line mouse deficient in immune cells, and a human T cell-engrafted mouse obtainable by the method. The present invention also
6613572 Agent for expression of long-term potentiation of synaptic transmission comprising compound havi September 2, 2003
The present invention relates to an agent for the expression of long-term potentiation of synaptic transmission, which contains a compound having a brain somatostatin activation property as an active ingredient and to a screening method of an agent for the expression of long-term potenti
6610748 Preventives/remedies for skin aging August 26, 2003
A composition for prophylaxis and therapy of dermal aging which comprises a substance having human leukocyte elastase inhibitory activity as an active ingredient.
6596738 Heterocyclic compound, composition and method for inhibiting adenosine deaminase July 22, 2003
Heterocyclic compounds of the following formula: ##STR1##wherein B is ##STR2## [wherein R.sub.1 is hydrogen or lower alkyl; R.sub.2 is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino(lower)alkyl A is lower alkylene;
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

 
 
  Recently Added Patents
Case for camera
Illuminating waveguide fabrication method
System and method for infrared dongle
Generalized AC-DC synchronous rectification techniques for single- and multi-phase systems
Processes for producing polyunsaturated fatty acids in transgenic organisms
Cooler
Cooling method and device for cooling a medium-voltage electrical installation in a protective sheath
  Randomly Featured Patents
Vertical and lateral restraint stabilizer for core shroud of boiling water reactor
Single beam full color electrophotography
Temperature sensor probe
Spanning tree protocol traffic in a transparent LAN
Junction box
Toilet lid cushion
Consumer product package with stabilizing insert
Coin rolling game apparatus
Rotary solenoid operated proportional flow control valve
Software test bed generation